Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 supplementary data 2 supplementary data 3 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2022 12 016 ."

"

 Financial disclosures: Hannah Collacott certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Hannah Collacott, Nicolas Krucien, and Sebastian Heidenreich are employees of Evidera, which was paid by Ferring Pharmaceuticals to conduct this study. Sebastian Heidenreich is a minority stockholder of Thermo Fisher Scientific, which owns Evidera. James W.F. Catto has received reimbursement for consultancy work from AstraZeneca, Ferring, Roche, and Janssen; speaker fees from BMS, MSD, Janssen, Astellas, Nucleix, and Roche; honoraria for membership of advisory boards from Ferring, Roche, Gilead, Photocure, BMS, QED Therapeutics, and Janssen; and research funding from Roche. He received reimbursement from Ferring Pharmaceuticals for his time spent advising on this study. Ola Ghatnekar is an employee of Ferring Pharmaceuticals. Financial disclosures:"

"

Financial disclosures: Hannah Collacott certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Hannah Collacott, Nicolas Krucien, and Sebastian Heidenreich are employees of Evidera, which was paid by Ferring Pharmaceuticals to conduct this study. Sebastian Heidenreich is a minority stockholder of Thermo Fisher Scientific, which owns Evidera. James W.F. Catto has received reimbursement for consultancy work from AstraZeneca, Ferring, Roche, and Janssen; speaker fees from BMS, MSD, Janssen, Astellas, Nucleix, and Roche; honoraria for membership of advisory boards from Ferring, Roche, Gilead, Photocure, BMS, QED Therapeutics, and Janssen; and research funding from Roche. He received reimbursement from Ferring Pharmaceuticals for his time spent advising on this study. Ola Ghatnekar is an employee of Ferring Pharmaceuticals. 

Funding/Support and role of the sponsor: This study was funded by Ferring Pharmaceuticals A/S, Denmark. The sponsor played a role in the design and conduct of the study; interpretation of the data; and preparation, review, and approval of the manuscript."